Four decades after the human immunodeficiency virus was first identified, the end of the epidemic could be in sight. Thanks to treatments and preventive medications, new infections worldwide have fallen dramatically, from 3.3 million at their peak in 1995 to 1.3 million in 2023. Now, with the arrival of a groundbreaking drug from Gilead Sciences, there’s serious talk about bringing new cases down to zero. The FDA approved Gilead Sciences’ Yeztugo (generic name lenacapavir) as PrEP medication to prevent HIV infection on June 19. But the company behind it has a lot of angry patients. Here's why: https://bit.ly/4jT1PdX